Lv31
296 积分 2023-09-18 加入
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
14分钟前
待确认
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
6天前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
9天前
已完结
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial
9天前
已完结
[Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer]
15天前
已完结
Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer
20天前
已完结
Chemotherapy for Advanced Breast Cancer – How Long Should it Continue?
21天前
已完结
Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
24天前
已关闭
Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
29天前
已关闭
Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer
1个月前
已完结
皖公网安备34019202002308
